Search clinical trials for: QVA149

Total 64 results

Novartis Pharmaceuticals

Completed

QVA Mechanistic Efficacy Study (Receptor Effects, Etc)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (MOVE)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients (CLAIM)

Chronic Obstructive Pulmonary Disease, COPD

Germany
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
Novartis Pharmaceuticals

Completed

A Study to Assess the Long-term Safety of QVA149 (ENLIGHTEN)

Chronic Obstructive Pulmonary Disease

Romania, Lithuania, Canada, France, Hungary, India, South Africa, Korea, Republic of, Latvia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

Asthma

Japan
Novartis Pharmaceuticals

Completed

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis

Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
Novartis

Completed

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

Asthma

Japan
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
University Medical Center Groningen
Novartis

Completed

Anti-inflammatory Effects Glycopyrronium

Asthma | Allergic Asthma

Netherlands
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma (QVM149)

Asthma

Germany, Netherlands, United Kingdom
United Arab Emirates University
Tawam Hospital

Completed

Effects of Antioxidants and B Vitamins Supplements on Inflammation in Obese Diabetic Patients

Obesity | Diabetes
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (BLAZE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Spain, Canada, United Kingdom
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (QUANTIFY)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Japan
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Asthma

Germany, Netherlands, United Kingdom, China, Romania, Bulgaria
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma

Asthma

Germany, Slovakia, Poland, Belgium, Estonia, Hungary, Latvia, Lithuania, Turkey, Canada, India, Netherlands, Ukraine, Russian Federation, Malaysia, Japan, Thailand
Novartis Pharmaceuticals

Completed

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Asthma

United States, Colombia, Korea, Republic of, Brazil, Hungary, Czech Republic, India, Slovakia, Peru
Novartis Pharmaceuticals

Completed

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ILLUMINATE)

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, Estonia, Hungary, Belgium, Czech Republic, Norway, Korea, Republic of, Lithuania
Novartis Pharmaceuticals

Completed

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

COPD

Korea, Republic of
Novartis Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Asthma
Novartis Pharmaceuticals

Completed

Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BRIGHT)

COPD

Germany, Spain
Novartis Pharmaceuticals

Completed

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

Mild Asthma

Germany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
Novartis Pharmaceuticals

Completed

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

Asthma

South Africa, Hungary
Novartis Pharmaceuticals

Completed

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (FLASH)

COPD

India, South Africa, Egypt, Australia, Israel, Lebanon, Turkey, Philippines, Malaysia, Taiwan, Saudi Arabia
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
Dr. Grace Parraga
Novartis Pharmaceuticals

Withdrawn

Investigating the Effects of QVM149 on MRI Ventilation Defects (XPERTT)

Asthma

Canada
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
Novartis
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

Asthma

France

3

Subscribe